Clinical Research in Cardiology

, Volume 103, Issue 2, pp 117–124 | Cite as

Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry

  • Britta Vogel
  • Michael Kirchberger
  • Martin Zeier
  • Felicitas Stoll
  • Benjamin Meder
  • Daniel Saure
  • Martin Andrassy
  • Oliver J. Mueller
  • Stefan Hardt
  • Vedat Schwenger
  • Anna Strothmeyer
  • Hugo A. Katus
  • Erwin Blessing
Original Paper

Abstract

Introduction

Renal sympathetic denervation (RDN) is a novel treatment option in patients with treatment-resistant arterial hypertension. A subset of recently published randomized and non-randomized trials indicates that RDN leads to sustained lowering of blood pressure (BP) under controlled study conditions. However, registry data that allow evaluation of safety and efficacy in a real-world setting are largely missing.

Methods

Sixty-three consecutive patients with treatment-resistant hypertension underwent RDN with the radiofrequency-based Symplicity™ catheter. As part of our prospective registry, treatment efficacy and safety were monitored after 3, 6, and 12 months.

Results

At 6 months follow-up, office systolic BP significantly improved by 19 + 23 mmHg as compared to baseline, while diastolic BP values reduced by 6 + 13 mmHg (p < 0.05). One year after RDN, office BP levels further improved (26 + 25 mmHg in systolic BP and 9 + 13 mmHg in diastolic BP, respectively), even though 19 patients had reduced the number and/or dosage of antihypertensive agents. The response rate, defined as reduction of office systolic BP of ≥10 mmHg, was 73 % after 6 months. Baseline BP was the only significant predictor of blood pressure response, whereas no correlation was found between the number of ablation points and the individual changes in office blood pressure. Interestingly, patients with challenging renal anatomy profited somewhat less from the procedure than those with “normal” renal anatomy. Procedure related adverse events occurred in three patients (4.7 %) and were limited to vascular access complications.

Conclusions

RDN with the Symplicity™ system is safe and effective in patients with treatment-resistant hypertension also in a real-world setting.

Keywords

Treatment-resistant hypertension Renal denervation therapy Registry Symplicity™ 

Supplementary material

392_2013_627_MOESM1_ESM.doc (28 kb)
Supplementary material 1 (DOC 27 kb)

References

  1. 1.
    Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M (2004) Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43(1):10–17. doi:10.1161/01.HYP.0000103630.72812.10 PubMedCrossRefGoogle Scholar
  2. 2.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349):1903–1913PubMedCrossRefGoogle Scholar
  3. 3.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention DE, Treatment of High Blood Pressure, National Heart L, Blood I, National High Blood Pressure Education Program Coordinating C (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252. doi:10.1161/01.HYP.0000107251.49515.c2 PubMedCrossRefGoogle Scholar
  4. 4.
    Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics C, Stroke Statistics S (2010) Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 121(7):948–954. doi:10.1161/CIRCULATIONAHA.109.192666 PubMedCrossRefGoogle Scholar
  5. 5.
    WHO (2009) Global health risks: mortality and burden of disease attributable to selected major risks. World Health Organization, GenevaGoogle Scholar
  6. 6.
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365(9455):217–223. doi:10.1016/S0140-6736(05)17741-1 PubMedGoogle Scholar
  7. 7.
    Sarafidis PA, Bakris GL (2008) Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 52(22):1749–1757. doi:10.1016/j.jacc.2008.08.036 PubMedCrossRefGoogle Scholar
  8. 8.
    Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Bohm M, Krum H (2011) Sympatho-renal axis in chronic disease. Clin Res Cardiol Off J Ger Card Soc 100(12):1049–1057. doi:10.1007/s00392-011-0335-y CrossRefGoogle Scholar
  9. 9.
    Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. New Engl J Med 361(9):932–934. doi:10.1056/NEJMc0904179 PubMedCrossRefGoogle Scholar
  10. 10.
    Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK (2011) Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol Off J Ger Card Soc 100(12):1095–1101. doi:10.1007/s00392-011-0346-8 CrossRefGoogle Scholar
  11. 11.
    Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671):1275–1281. doi:10.1016/S0140-6736(09)60566-3 PubMedCrossRefGoogle Scholar
  12. 12.
    Symplicity HTNI (2011) Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57(5):911–917. doi:10.1161/HYPERTENSIONAHA.110.163014 CrossRefGoogle Scholar
  13. 13.
    Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376(9756):1903–1909. doi:10.1016/S0140-6736(10)62039-9 CrossRefGoogle Scholar
  14. 14.
    Krum HSM, Sobotka P, Esler M, Mahfoud F, Boehm M, Dunlap M, Rocha-Singh K, Katholi R (2012) Long-term follow up of catheter-based renal denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol 60(17):B3CrossRefGoogle Scholar
  15. 15.
    Esler MDKH, Schlaich MP, Schmieder RE, Boehm M, Sobotka P (2012) Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18 months follow up of the Symplicity HTN-2 trial. Eur Heart J 33:181Google Scholar
  16. 16.
    Kandzari DE, Bhatt DL, Sobotka PA, O’Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G (2012) Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 35(9):528–535. doi:10.1002/clc.22008 PubMedCrossRefGoogle Scholar
  17. 17.
    Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18):1940–1946. doi:10.1161/CIRCULATIONAHA.110.991869 PubMedCrossRefGoogle Scholar
  18. 18.
    Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A (2011) Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58(4):559–565. doi:10.1161/HYPERTENSIONAHA.111.173799 PubMedCrossRefGoogle Scholar
  19. 19.
    Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, Lambert E, Chopra R, Socratous F, Hennebry S, Eikelis N, Bohm M, Krum H, Lambert G, Esler MD, Sobotka PA (2011) Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 29(5):991–996. doi:10.1097/HJH.0b013e328344db3a PubMedCrossRefGoogle Scholar
  20. 20.
    Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, Sobotka PA, Gawaz M, Bohm M (2012) Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol Off J Ger Card Soc 101(1):63–67. doi:10.1007/s00392-011-0365-5 CrossRefGoogle Scholar
  21. 21.
    Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, Bohm M (2012) Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 60(1):172–178. doi:10.1161/HYPERTENSIONAHA.112.191965 PubMedCrossRefGoogle Scholar
  22. 22.
    Zhao Q, Yu S, Zou M, Dai Z, Wang X, Xiao J, Huang C (2012) Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. J Interv Card Electrophysiol Int J Arrhythm Pacing 35(2):119–125. doi:10.1007/s10840-012-9717-y CrossRefGoogle Scholar
  23. 23.
    Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR, Wirth K, Bohm M (2013) Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension 61(1):225–231. doi:10.1161/HYPERTENSIONAHA.111.00182 PubMedCrossRefGoogle Scholar
  24. 24.
    Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, Hoppe UC (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59(10):901–909. doi:10.1016/j.jacc.2011.11.034 PubMedCrossRefGoogle Scholar
  25. 25.
    Task Force M, Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Council ESHS, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Guidelines ESCCfP, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219. doi:10.1093/eurheartj/eht151 PubMedCrossRefGoogle Scholar
  26. 26.
    Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Bohm M (2013) Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 34(28):2149–2157. doi:10.1093/eurheartj/eht154 PubMedCrossRefGoogle Scholar
  27. 27.
    Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C (2013) Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol 9(Suppl R):R58–R66. doi:10.4244/EIJV9SRA11 Google Scholar
  28. 28.
    Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Bohm M (2012) Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60(2):419–424. doi:10.1161/HYPERTENSIONAHA.112.193870 PubMedCrossRefGoogle Scholar
  29. 29.
    Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Bohm M (2013) Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 128(2):132–140. doi:10.1161/CIRCULATIONAHA.112.000949 PubMedCrossRefGoogle Scholar
  30. 30.
    Kaltenbach B, Franke J, Bertog SC, Steinberg DH, Hofmann I, Sievert H (2012) Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. doi:10.1002/ccd.24557 Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Britta Vogel
    • 1
  • Michael Kirchberger
    • 1
  • Martin Zeier
    • 2
  • Felicitas Stoll
    • 1
  • Benjamin Meder
    • 1
  • Daniel Saure
    • 3
  • Martin Andrassy
    • 1
  • Oliver J. Mueller
    • 1
  • Stefan Hardt
    • 1
  • Vedat Schwenger
    • 2
  • Anna Strothmeyer
    • 1
  • Hugo A. Katus
    • 1
  • Erwin Blessing
    • 1
  1. 1.Medical Clinic IIIUniversity of HeidelbergHeidelbergGermany
  2. 2.Medical Clinic IUniversity of HeidelbergHeidelbergGermany
  3. 3.Department of Medical BiometryUniversity of HeidelbergHeidelbergGermany

Personalised recommendations